Ads
related to: biogen's
Search results
Small Business - Picayune Item | Picayune Item
The Picayune Item· 41 minutes agoNEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- Leading law firm Bleichmar Fonti & Auld LLP announces the upcoming July 22, 2024, deadline in the Biogen Inc. (Nasdaq: BIIB) Securities Class Action Lawsuit. If you invested in Biogen, you are encouraged
European Commission approves Biogen’s QALSODY for ALS treatment
Pharmaceutical Technology via Yahoo Finance· 5 days agoThe European Commission (EC) has granted marketing authorisation for Biogen's QALSODY (tofersen) an...
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on...
Morningstar· 6 days agoLaw Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Biogen Inc. (“Biogen” or the “Company”) (NASDAQ: BIIB) securities between ...
European Commission grants marketing approval to Biogen's ALS drug
Reuters via Yahoo News· 6 days agoThe approval is based on a 108-patient trial that showed Qalsody reduced levels of a neurofilament...
Is Biogen Inc (BIIB) Set to Underperform? Analyzing the Factors
Guru Focus· 5 days agoLong-established in the Drug Manufacturers industry, Biogen Inc (BIIB, Financial) has enjoyed a stellar reputation. Notably, its diminished rankings in financial strength, growth, and valuation ...
Europe Approves Biogen's Tofersen For Adult Patients With Rare Type Of Neurodegenerative Disorder
Benzinga via Yahoo Finance· 5 days agoOn Thursday, the European Commission granted marketing authorization under exceptional circumstances...
BIOGEN ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been...
Benzinga· 4 days agoBragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Biogen Inc. ("Biogen" or the "Company") ...
Biogen (BIIB) Gets EU Approval for Rare Disease Drug Qalsody
Zacks via Yahoo Finance· 5 days agoBiogen’s stock was up 2.6% on Thursday in response to Qalsody’s approval in the EU. Biogen’s stock...
Biogen Receives European Commission Approval for QALSODY® (tofersen), the First Therapy to Treat a...
Morningstar· 6 days agoBiogen Inc. (Nasdaq: BIIB) announced the European Commission (EC) has granted marketing authorization under exceptional circumstances and maintained orphan designation for QALSODY® (tofersen ...
Is Eli Lilly Stock A Buy On A Recent Crohn's Disease-Related Rally?
Investor's Business Daily· 6 days agoThe decision effectively pushes back the approval decision, which was expected in the first quarter....